EUCTR2010-018861-53-NL
Active, not recruiting
Not Applicable
Efficacy and safety of the calcimimetic Cinacalcet in the management of patients with Primary Hyperparathyroidism due to a MEN-1 mutation - Cinacalcet in MEN-I PHPT
eiden University Medical Center0 sitesFebruary 8, 2010
ConditionsPatients with primary hyperparathyroidism due to a germline mutation in the MEN-1 geneMedDRA version: 12.1Level: LLTClassification code 10036693Term: Primary hyperparathyroidism
DrugsMimpara ®
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Patients with primary hyperparathyroidism due to a germline mutation in the MEN-1 gene
- Sponsor
- eiden University Medical Center
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •A diagnosis of primary hyperparathyroidism due to a genetically confirmed germline mutation in the MEN\-1 gene
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •\- Sporadic primary hyperparathyroidism
- •\- Autonomous hyperparathyroidism due to chronic renal failure or vitamin D deficiency
- •\- Absence of genetic confirmation of a mutation in the MEN\-1 gene
- •\- Contraindications for MRI scanning, such as metallic fragments, pacemakers and defibrillators, nerve stimulators, intracranial clips, cochlear implants. ferromagnetic implants or claustrophobia.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
Efficacy and safety of treatment with Cinacalcet in patients with Primary Hyperparathyroidism due to a MEN-1 mutatiohyperactive parathyroid glandsprimary hyperparathyroidism1008362410033949NL-OMON34871eids Universitair Medisch Centrum20
Recruiting
Not Applicable
Effectiviteit en veiligheid van behandeling met cinacalcet bij patiënten met primaire hyperparathyreoïdie door een MEN-I mutatie.MEN-1Primary HyperparathyroidismPrimair HyperparathyreoidieCinacalcetCaSRNL-OMON23587eiden University Medical CenterDutch MEN-1 Study Group30
Not yet recruiting
Phase 2
comparative evaluation of three different root canal medicaments in reducing paiHealth Condition 1: K040- PulpitisCTRI/2024/08/071970Dr Itika Jain
Completed
Phase 3
Comparative evaluation of the efficacy of calcium hydroxide with resin modified glass ionomer versus TheraCal in indirect pulp cap: a clinical trial studyIRCT20231025059853N1Shahre-kord University of Medical Sciences50
Completed
Phase 4
A study of long-term efficacy and safety of calcipqotriol hydrate/betamethasone dipropionate ester fixed dose combination product in patients with psoriasis vulgarispsoriasis vulgarisJPRN-UMIN000025083Fukuoka University100